# White matter protection by inhibitors of glial scar formation in perinatal hypoxia ischemia

> **NIH NIH R01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2022 · $361,900

## Abstract

Project Summary
Survivors of preterm birth are commonly diagnosed with persistent white matter injury (WMI) that leads to a
failure of normal myelination. Myelination failure results in life long motor and neurobehavioral disabilities. The
central feature of WMI is the so-called “glial scar,” an inhibitory barrier generated by reactive astrocytes, which
causes myelination failure by blocking the maturation of oligodendrocyte progenitors. It is our long-term
objective to develop novel therapies to prevent myelination failure by preventing glial scar formation.
There are no therapeutic strategies to prevent early formation of diffuse reactive astrogliosis before it
chronically blocks myelination.
WMI disrupts the integrity of the hyaluronic acid (HA) backbone of the extracellular matrix. We have defined a
novel pathway through which small ~5 kDa HA oligomers (HA5) regulate the proliferation of astroglial
progenitors and promote reactive astrogliosis. Through the enzyme tumor
necrosis
factor-
(TNF)
stimulated
gene-6 (TSG-6), HA5 serves as a sink that traps heavy chain (HC) protein subunits of the inter-alpha-inhibitor
protein (II) complex. This reaction generates unstable intermediates of II that release HC. We have
identified novel approaches to block this TSG-6-dependent pathway to markedly attenuate the formation of the
glial scar. Our over-riding hypothesis is that HA5-mediated HC release promotes reactive astrogliosis
via a src family kinase-dependent pathway. We propose three specific aims to test this hypothesis. In aim
1, we hypothesize that hyaluronidase activation in the glial scar promotes the formation of HA5. We will
determine the hyaluronidases (HYAL) that generate HA5 to promote formation of the glial scar and determine if
a broad spectrum HYAL inhibitor reduces astrogliosis in response to WMI. In aim 2, we will test the
hypothesis that HA5 promotes astrocyte proliferation and reactive astrogliosis through TSG-6-dependent
release of heavy chains derived from II. We will determine if astrocyte proliferation in WMI is dependent on
TSG-6 expression that promotes astrogliosis in vitro and in vivo via an HC-dependent mechanism. In aim 3,
we hypothesize that activation of TSG-6 mediates glial scar formation via activation of src family kinases. We
will first determine if a TSG-6 blocking antibody inhibits proliferation of astrocyte progenitors in vivo. We will
test a src kinase inhibitor, currently in clinical trials, as a novel strategy to block glial scar formation and
promote myelination. At the conclusion of these studies, we expect to define new therapeutic strategies to
intervene during early WMI to prevent formation of the glial scar and promote myelination. Given that reactive
astrogliosis is a central feature of many forms of CNS injury, our findings may have potential benefit for other
pediatric and adult neurological disorders with prominent WMI.

## Key facts

- **NIH application ID:** 10404658
- **Project number:** 5R01NS116674-03
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Stephen Arthur Back
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $361,900
- **Award type:** 5
- **Project period:** 2020-05-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10404658

## Citation

> US National Institutes of Health, RePORTER application 10404658, White matter protection by inhibitors of glial scar formation in perinatal hypoxia ischemia (5R01NS116674-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10404658. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*